Insomnia Treatment Market, Size, Share, Opportunities and Forecast, 2020-2027

SKU: DHC290 | Last Updated On: Sep 08 2020 | No. of Pages: 182 | Available Formats

> Global Insomnia Treatment Market Expected to reach a high CAGR of 5.2% By 2027: DataM Intelligence

Global Insomnia Treatment Market is segmented By Treatment Type (Over the Counter Sleep Aids, Prescription Sleep Aids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027

 

Market Overview

The Global Insomnia Treatment Market is expected to grow at a high CAGR of 5.2% during the forecasting period (2020-2027). 

Insomnia is a sleeping disorder in which an individual has difficulty falling asleep or staying asleep. People with insomnia can feel dissatisfied with their sleep and experience symptoms such as fatigue, low energy, difficulty concentrating, mood disturbances, and decreased performance in work or at school. The increasing number of sleep disorders, affordable reimbursement scenario for drugs prescribed in insomnia treatment, rising health awareness leading to effective insomnia treatment, and developing healthcare infrastructure are some of the factors driving the growth of the market. Insomnia disorder is an economic burden and public health concern affecting up to one-third of the population of the United States. According to a study conducted by the University of Pennsylvania School of Medicine in 2018, the latest data shows that 25% of the population experience acute insomnia each year, with 6% finding that the condition develops into chronic insomnia over the course of the year.

Market Growth

According to results from the America Insomnia Survey, published by the US National Library of Medicine, this $63 billion in lost revenue comes from a reduced productivity level or absence and is equivalent to the whole population missing 252.7 days of work each year. Based on treatment type, prescription sleep aids are estimated to dominated the insomnia treatment market over the forecast period, owing to rising prevalence of insomnia, increasing stress, addiction, etc., which if untreated will eventually result in chronic illness. It is estimated that the number of acute insomnia cases would rise from 121,799,911 in 2013 to 130,482,156 in 2023, with the number of chronic insomnia cases also expected to see the same rise of 0.7%. The insomnia drugs comprise of a wide range of patented drugs, as well as generics. The patented drugs hold a larger share in developed regions, owing to the better reimbursement policies. For instance, in July 2019, Dr Reddy's Laboratories has launched generic Ramelteon tablets used for the treatment of insomnia in the US market. The company has launched Ramelteon tablets in the strength of 8 mg after getting approval by the United States Food and Drug Administration (USFDA). The product is a generic version of Takeda Pharmaceutical Company's Rozerem tablets in the same strength, it added.

Market Key Players

The global insomnia treatment market is highly fragmented due to the presence of multiple generic manufacturers. Some major players in the market are Merck & Co., Mylan N.V., Paratek Pharmaceuticals, Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Ltd., Teva Pharmaceutical Industries Ltd., Vanda Pharmaceuticals Inc, among others. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the insomnia treatment market globally.

For instance,

  • On December 23rd, 2019, Eisai Co., Ltd. Received the that the U.S. Food and Drug Administration (FDA) approval for the new drug application for its in-house discovered and developed orexin receptor antagonist DAYVIGOTM (lemborexant). DAYVIGO was approved for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults. In the United States, DAYVIGO will be commercially available in 5 mg and 10 mg tablets following scheduling by the U.S. Drug Enforcement Administration (DEA), which is expected to occur within 90 days.
  • In May 2019, Merck announced the results of a Phase 3 trial evaluating the efficacy and safety of BELSOMRA® (suvorexant) C-IV for the treatment of insomnia in people with mild-to-moderate Alzheimer’s disease dementia. This is the first dedicated Phase 3 polysomnography study of an insomnia medication in people with mild-to-moderate Alzheimer’s disease dementia, and in the trial, BELSOMRA met its primary and secondary efficacy endpoints.

Why Purchase the Report?

  • Visualize the composition of the Global Insomnia Treatment Market across each indication, regarding type and treatment options, highlighting the vital commercial assets and players.

  • Identify business opportunities in Global Insomnia Treatment Market by analyzing trends and co-development deals.

  • Excel data sheet with thousands of data points of the Global Insomnia Treatment Market – level 4/5 segmentation.

  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • Product mapping in excel for the principal products of all major market players

Target Audience

  • Equipment Suppliers/ Buyers

  • Service Providers/ Buyers

  • Industry Investors/Investment Bankers

  • Education & Research Institutes

  • Research Professionals

  • Emerging Companies

  • Manufacturers

 

Table of Contents 

  1. Insomnia Treatment Market Methodology and Scope

    1. Research methodology
    2. Scope of the Report
  2. Insomnia Treatment Market Definition and Overview

  3. Insomnia Treatment Market – Executive Summary

    1. Market Snippet by Treatment Type
    2. Market Snippet by Distribution Channel
    3. Market Snippet by Region
  4. Insomnia Treatment Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. Rising stress owing to changing lifestyle
        2. Side-effects associated with certain OTC and prescription medication
      2. Restraints
        1. Misconceptions towards the seriousness of insomnia
      3. Opportunity
      4. Impact Analysis
  5. Insomnia Treatment Market – Industry Factors

    1. Porter’s Five Forces
    2. Regulatory & Reimbursement Analysis
    3. Patent Analysis
    4. Supply Chain Analysis
    5. Pricing Analysis
    6. Unmet Needs
    7. Product Innovation, if any
    8. Comparative Scenario (2019, 2022, 2026)
  6. Insomnia Treatment Market – By Treatment Type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      2. Market Attractiveness Index, By Treatment Type
    2. Over the Counter (OTC) Sleep Aids*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2018-2026 and Y-o-Y Growth Analysis (%), 2020-2027
        1. Melatonin
        2. Antihistamines
        3. Dietary Supplement
        4. Others
    3. Prescription Sleep Aids
      1. Benzodiazepines
      2. Antidepressants
      3. Orexin Antagonist
      4. Others
  7. Insomnia Treatment Market – By Distribution Channel

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      2. Market Attractiveness Index, By Distribution Channel
    2. Hospital Pharmacies*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2018-2026 and Y-o-Y Growth Analysis (%), 2020-2027
    3. Retail Pharmacies and Drug Stores
    4. Online Pharmacies
  8. Insomnia Treatment Market – By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    3. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    4. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Spain
        5. Italy
        6. Rest of Europe
    5. Asia-Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia-Pacific
    6. Middle East & Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  9. Insomnia Treatment Market – Competitive Landscape

    1. Competitive Scenario
    2. Competitor Strategy Analysis
    3. Comparative Product Portfolio Analysis
    4. Market Positioning/Share Analysis
    5. Mergers and Acquisitions Analysis
  10. Insomnia Treatment Market – Company Profiles

    1. Merck & Co.*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Mylan N.V.
    3. Sanofi S.A.
    4. Paratek Pharmaceuticals, Inc.
    5. Pfizer Inc.
    6. Teva Pharmaceutical Industries Ltd.
    7. Sumitomo Dainippon Pharma Co., Ltd.
    8. Takeda Pharmaceutical Company Ltd.
    9. Vanda Pharmaceuticals Inc.
    10. Ebb Therapeutics
  11. Insomnia Treatment Market – DataM

    1. Appendix
    2. About Us and Services
    3. Contact Us
Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!

linkedinpinterest